Metabolic and morphologic disorders in patients treated with highly active antiretroviral therapy since primary HIV infection

Annals of the New York Academy of Sciences

Volumn 946, Issue , 2001, Pages 214-222

  Narciso, Pasquale ^a   Tozzi, Valerio ^a   D'Offizi, Gianpiero ^a   De Carli, Gabriella ^a   Orchi, Nicoletta ^a   Galati, Vincenzo ^a   Vincenzi, Laura ^a   Bellagamba, Rita ^a   Carvelli, Chiarina ^a   Puro, Vincenzo ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antiretroviral agents; HIV; Lipodystrophy; Metabolic disorders; Primary infection

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; GLUCOSE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; BODY BUILD; BODY MASS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; METABOLIC DISORDER; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; QUESTIONNAIRE; SELF REPORT; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0035202435     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03914.x     Document Type: Conference Paper

References (17)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Visceral abdominal-fat accumulation associated with use of indinavir
3. Buffalo hump and facial wasting in HIV
4. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystropy, hyperlipidaemia, and diabetes mellitus: A cohort study
5. Fat distribution and metabolic changes in patients with HIV infection
6. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
7. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrohphy, hyperlipidaemia, and insuline resistance
8. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
9. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
10. Lipodystrophy following antiretroviral therapy of primary HIV infection
11. Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection
12. Incidence of clinical lipodystrophy in HIV-1-infected patients treated during primary infection
13. Risk of lipodystrophy in HIV-infected patients treated with protease inhibitors: A prospective cohort study
14. Metabolic effects of indinavir in healthy HIV-seronegative men
15. Effect of ritonavir on lipids and postheparin lipase activities in normal subjects
16. Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals